AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1(Canceled).

2(Currently Amended). The method according to claim <u>28</u>4, further comprising delivering an estrogen in combination with the compound of formula I.

3(Currently Amended). The method according to claim 24, wherein the estrogen is delivered prior to or subsequent to the compound of formula I.

4-7(Canceled).

8(Withdrawn and Currently Amended). The method according to Claim 28 +, wherein said compound is selected from the group consisting of 6 (3-Chlorophenyl) 4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-thione, 4 (4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-5 fluorobenzonitrile, 3 (4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-5 fluorobenzonitrile, 3 (4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl) benzonitrile, 6 (3-fluorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione, 5 (4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-1-earboxylate, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile, [6-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-pyridin-

2 yl]acetonitrile, 5 (4,4 dimethyl 2 thioxo 1,4 dihydro 2H-3,1 benzoxazin 6 yl) 1Hpyrrole 2 carbothiamide, 5 (4,4 Dimethyl 2 thioxo 1,4 dihydro 2H benzo[d][1,3]oxazin-6-yl) thiophene-3-carbonitrile, 5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-ethyl-1H-pyrrole-2-carbonitrile, 4 (1,2-Dihydro-2-thioxospiro[4H-3,1benzoxazin 4,1 cyclohexan] 6-yl) 2-thiophenecarbonitrile, 5 (4,4-Dimethyl-2 thioxo-1,4-dihydro 2H-3,1-benzoxazin 6-yl) 2-fluorobenzonitrile, 6 (5-Bromopyridin-3-yl) 4,4dimethyl 1,4 dihydro 2H-3,1 benzoxazine 2 thione, 6 (3 Chloro 5 fluorophenyl) 4,4 dimethyl-1,4-dihydro 2H-3,1-benzoxazine 2-thione, 6-(3-Bromo-5-methylphenyl)-4,4dimethyl 1,4 dihydro 2H 3,1 benzoxazine 2-thione, 6 (3-Bromo 5trifluoromethoxyphenyl) 4,4 dimethyl 1,4 dihydro 2H 3,1 benzoxazine 2 thione, 3 (1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1-cyclohexan] 6-yl)-5-fluorobenzonitrile, 3-(4,4 Dimethyl-2 thioxo-1,4 dihydro-2H-3,1-benzoxazin-6 yl)-5 methylbenzonitrile, 6-(3,5 Dichlorophenyl) 4,4 dimethyl-1,4 dihydro-2H-3,1 benzoxazine 2 thione, 5 (4,4-Dimethyl-1,2 thioxo-1,4 dihydro-2H 3,1-benzoxazin-6-yl)isophthalonitrile, 5 (4,4-Dimethyl-2 thioxo-1,4-dihydro 2H-3,1-benzoxazin-6 yl)-2 furonitrile, 4,4-Diethyl-6 (3nitrophenyl) 1,4 dihydro 2H 3,1 benzoxazine 2-thione, 6 (3-Chlorophenyl) 4-methyl 4phenyl 1,4 dihydro 2H 3,1 benzoxazine 2 thione, 4 Allyl 6 (3 chlorophenyl) 4 methyl-1,4-dihydro 2H-3,1-benzoxazine-2-thione, 3-Chloro-5-(4,4-dimethyl-2-thioxo-1,4dihydro 2H-3,1 benzoxazin 6 yl)benzonitrile, 6 (3,5 Difluorophenyl)-4,4 dimethyl 1,4 dihydro 2H-3,1-benzoxazine-2-thione, 6-(3-Fluoro-5-methoxyphenyl)-4,4-dimethyl-1,4dihydro 2H 3,1-benzoxazine 2 thione, 3 (4,4 Dimethyl 2 thioxo 1,4 dihydro 2H 3,1benzoxazin-6 yl) 5 methoxybenzonitrile, 6 (3 Fluorophenyl) 4,4 dimethyl 1,4 dihydro-2H-3,1-benzoxazine 2-thione, 6-[3-Fluoro-5 (trifluoromethyl)phenyl] 4,4-dimethyl 1,4dihydro 2H-3,1 benzoxazine 2 thione, 6 (2 Fluorophenyl) 4,4 dimethyl-1,4 dihydro 2H 3,1-benzoxazine 2 thione, 6 (3,4-Difluorophenyl)-4,4 dimethyl-1,4 dihydro 2H 3,1benzoxazine 2-thione, 6 (4-Fluorophenyl) 4,4-dimethyl-1,4-dihydro-2H-3,1benzoxazine 2 thione, 3 (4,4 Dimethyl 2 thioxo 1,4 dihydro 2H 3,1 benzoxazin 6 yl)-4fluorobenzonitrile, 6 (2,3-Difluorophenyl) 4,4-dimethyl-1,4-dihydro-2H-3,1benzoxazine 2-thione, 3-(8-Bromo-4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-

benzoxazin 6 yl) 5 fluorobenzonitrile, 4,4 Dimethyl 6 (3 nitrophenyl) 1,4 dihydro 2H-3,1-benzoxazine 2 thione, 6-(3 Chlorophenyl) 4,4-diethyl 1,4-dihydro 2H-3,1benzoxazine 2 thione, 6 (3 Methoxyphenyl) 4,4 dimethyl 1,4 dihydro 2H-3,1benzoxazine 2 thione, 6 (2 Chlorophenyl) 4,4 dimethyl 1,4 dihydro 2H 3,1 benzoxazine 2-thione, 4-Benzyl 6 (3-chlorophenyl) 4-methyl 1,4-dihydro 2H 3,1benzoxazine 2 thione, 6 (3 Bromo 5 fluorophenyl) 4,4 dimethyl 1,4 dihydro 2H 3,1 benzoxazine 2 thione, 5 (4,4 Dimethyl 2 thioxo 1,4 dihydro-2H 3,1 benzoxazin 6 yl) thiophene 2 carbonitrile, 3 Fluoro 5 (8 fluoro 4,4 dimethyl 2 thioxo 1,4 dihydro 2H-3,1-benzoxazin-6-yl)benzonitrile, 3 (1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1eyclohexan] 6-yl)benzonitrile, 5-(1,2-Dihydro 2-thioxospiro[4H-3,1-benzoxazine-4,1eyclohexan] 6 yl) 4 methyl 2 thiophenecarbonitrile, 5 (1,2 Dihydro 2 thioxospiro[4H-3,1-benzoxazine-4,1-cyclohexan] 6-yl) 2-thiophenecarbonitrile, 6-(3-Chloro-4fluorophenyl) 4,4 dimethyl 1,4 dihydro 2H-3,1 benzoxazine 2 thione, 5 (4,4 Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl) 4-propylthiophene 2 carbonitrile, 4 (4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin 6-yl) 2-furonitrile, 4-Butyl-5 (4,4dimethyl-2 thioxo-1,4 dihydro-2H-3,1 benzoxazin-6-yl)thiophene-2 carbonitrile, 6 (3-Bromophenyl) 4,4-dimethyl 1,4 dihydro 2H-3,1-benzoxazine 2-thione, and 2-(4,4-Dimethyl 2 thioxo 1,4 dihydro 2H 3,1 benzoxazin 6 yl)thiophene 3 carbonitrile, or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

9(Currently Amended). The method according to claim <u>28</u> 1, wherein said compound is 5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

10(Withdrawn and Currently Amended). The method according to claim $\underline{28}$ 1, wherein R^1 and R^2 are fused to form a carbon-based 3 to 6 membered saturated spirocyclic ring.

11-27(Canceled).

28(New). A method of treating acne and/or hirsutism comprising the step of delivering to a mammal in need thereof a composition comprising a compound of formula II and a physiologically compatible carrier, wherein said compound of formula II is of the structure:

wherein:

R^{1'} is selected from the group consisting of methyl, ethyl, and trifluoromethyl;
R^{2'} is selected from the group consisting of methyl, ethyl, and trifluoromethyl; or
R^{1'} and R^{2'} are joined to form a spirocyclic ring containing 3 to 7 carbon atoms;
and

 $R^{3'}$ is C_1 to C_4 alkyl; and tautomers, prodrugs, metabolites, or pharmaceutically acceptable salts thereof.

29(New). The method according to claim 28, wherein said compound is 5-(4-ethyl-4-methyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, 5-(4,4-diethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, 1-methyl-5-(2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclobutan]-6-yl)-1H-pyrrole-2-carbonitrile, 1-methyl-5-(2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclohexan]-6-yl)-1H-pyrrole-2-carbonitrile, 1-methyl-5-(2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclopentan]-6-yl)-1H-pyrrole-2-carbonitrile, 1-methyl-5-[2-thioxo-4,4-bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazine-6-yl]-1H-pyrrole-2-carbonitrile, a tautomer, prodrug, metabolite, or pharmaceutically acceptable salts thereof.

AHPWA23AUSA

30(New). The method according to claim 9, wherein said prodrug is an ester or carbamate.

31(New). The method according to claim 28, wherein said prodrug is an ester or carbamate.